类药物提卡格勒和狂肌溶解:巧合还是药物相互作用?
Ramesh Patel1, Jai Bharat Sharma1, Saraswati Rajput2
1Department of Cardiology, Geetanjali Medical College and Hospital, Udaipur, India.
Journal of lipid and atherosclerosis
|February 1, 2024
概括
提卡格勒勒与高强度他类药物结合使用可能会增加狂肌衰竭和损伤的风险,特别是在接受皮肤透光冠状动脉血管形成手术 (PTCA) 的患者中. 仔细考虑这种药物相互作用对于防止严重后果至关重要.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 腎臟病學 (nephrology) 是一種醫學.
背景情况:
- 类药物对于治疗动脉样硬化心血管疾病至关重要.
- 增加他类药物的使用与更多的不良影响相关,特别是肌肉症状.
- 蒂卡格勒勒和高强度他类药物之间潜在的药物相互作用可能会加剧他类药物诱导的狂宫痛解.
研究的目的:
- 为了研究在皮肤透光冠状动脉血管塑造 (PTCA) 期间经历了他类药物诱导的狂宫溶解的患者的特征.
主要方法:
- 一项观察性研究涉及1862名患者,他们在一年内接受了PTCA.
- 分析患者数据,重点关注那些经历高强度他类药物治疗不良影响的人.
主要成果:
- 四名接受高强度他类药物治疗的患者在急性冠状动脉综合征后出现肌肉衰弱和损伤.
- 这四名患者都同时服用提卡格勒罗.
- 两名患者死亡;另外两名患者接受了支持性护理和替代性降脂药物治疗.
结论:
- 同时使用提卡格雷勒和高强度他类药物会增加拉布地质溶解和损伤的风险.
- 需要进一步的药理动力学研究来确认因果关系并预测药物相互作用.
- 避免这种组合可以防止致命的结果.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
661
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
661
Factors Affecting Protein-Drug Binding: Drug Interactions
140
Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
140
Combined Effects of Drugs: Synergism
3.9K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
3.9K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
525
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
525
Combined Effects of Drugs: Antagonism
8.5K
The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
8.5K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
515
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
515


